.....Selected Scientific Papers

• Prelevic GM, Wurzburger MI, Balint-Peric Lj, Nesic JS
  Inhibitory effect of Sandostatin on secretion of Luteinizing hormone and ovarian steroids in Polycystic Ovary Syndrome
  The Lancet 1990;336:900-903.
  
  
• Prelevic GM, Wurzburger MI, Balint-Peric Lj, Ginsburg J
  Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in womens with Polycystic Ovary Syndrome
  Hormone Research 1992;37:125-131.
  
  
• Prelevic GM & Beljic T
  The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women
  Maturitas 1994; 20: 37-44.
  
  
• Prelevic GM, Ginsburg J, Maletic D, et al.
  The effects of the somatostatin analogue octreotide on ovulatory performance in women with Polycystic Ovary Syndrome
  Human Reproduction 1995; 10:28-32.
  
  
• Prelevic GM, Beljic T, Balint-Peric Lj, Ginsburg J
  Cardiac flow velocity in women with Polycystic Ovary Syndrome
  Clinical Endocrinology, 1995; 43; 677-681.
  
  
• Prelevic GM, Beljic T, Balint-Peric Lj, Ginsburg J
  Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus
  Maturitas, 1998; 28: 271-276.
  
  
• Agrawal R, Prelevic GM, Conway GS et al.
  Serum vascular endothelial growth factor (VEGF) concentrations in postmenopausal women: The effect of hormone replacement therapy
  Fertility & Sterility, 2000;73:56-60.
  
  
• Brooke-Wavell K, Prelevic GM, Bartram C, Ginsburg J
  Influence of physical activity on response of bone mineral density to 5 year tibolone
  Maturitas 2000; 35:229-235.
  
  
• Prelevic GM, P Kwong, DJ Byrne et al.
  A cross-sectional study of the cardiovascular disease risk profile in heaqlthy postmenopausal women – differential effects of menopausal hormone replacement therapy
  Fertility & Sterility 2002; 77: 945-951.
  
  
• Randeva HS, Lewandowski KC, Drzewoski J, Prelevic GM
  Exercise decreases plasma total homocysteine in overweight young women with Polycystic Ovary Syndrome
  Journal of Endocrinology & Metabolism 2002; 87: 4496-4501.
  
  
• Agrawal R, Sharma S, Bekir J, Conway G, Bailey J, Balen AH, Prelevic GM
  Prevalence of Polycystic ovaries and Polycystic Ovary Syndrome in lesbian women compared with heterosexual women
  Fertility and Sterility, 2004; 82: 1352-1357.
  
  
• Lewandowski KC, Komorowski J, Prelevic GM, Randeva HS
  Increased circulating levels of matrix metalloproteinase-2 and -9 in women with Polycystic Ovary Syndrome
  Journal of Endocrinology and Metabolism 2006; 91:1173-1177.
  
  
• Lewandowski KC, Komorowski J, Prelevic GM, Randeva HS
  Effects of hormone replacement therapy, type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women
  Journal of Endocrinology and Metabolism, 2006; 91:3123-3130.
  
  
• Kocjan T, Tan T, Conway G, Prelevic GM
  Vitamin D status in patients with ostepenia or osteoporosis – an audit of an endocrine clinic International
  Journal for Vitamin and Nutrition Research, 2006; 76:307-313.
  
  
• Liao L-M, Nesic J, Chadwick P, Brooke-Wavell K & Prelevic GM
  Exercise and body image distress in overweight and obese women with Polycystic Ovary Syndrome
  Gynaecological Endocrinology, 2008: 24: 555-561.